236 related articles for article (PubMed ID: 16630986)
1. Oral rapamycin after coronary bare-metal stent implantation to prevent restenosis: the Prospective, Randomized Oral Rapamycin in Argentina (ORAR II) Study.
Rodriguez AE; Granada JF; Rodriguez-Alemparte M; Vigo CF; Delgado J; Fernandez-Pereira C; Pocovi A; Rodriguez-Granillo AM; Schulz D; Raizner AE; Palacios I; O'Neill W; Kaluza GL; Stone G;
J Am Coll Cardiol; 2006 Apr; 47(8):1522-9. PubMed ID: 16630986
[TBL] [Abstract][Full Text] [Related]
2. Pilot study of oral rapamycin to prevent restenosis in patients undergoing coronary stent therapy: Argentina Single-Center Study (ORAR Trial).
Rodriguez AE; Alemparte MR; Vigo CF; Pereira CF; Llaurado C; Russo M; Virmani R; Ambrose JA
J Invasive Cardiol; 2003 Oct; 15(10):581-4. PubMed ID: 14519892
[TBL] [Abstract][Full Text] [Related]
3. Randomized double-blind comparison of sirolimus-eluting stent versus bare-metal stent implantation in diseased saphenous vein grafts: six-month angiographic, intravascular ultrasound, and clinical follow-up of the RRISC Trial.
Vermeersch P; Agostoni P; Verheye S; Van den Heuvel P; Convens C; Bruining N; Van den Branden F; Van Langenhove G
J Am Coll Cardiol; 2006 Dec; 48(12):2423-31. PubMed ID: 17174178
[TBL] [Abstract][Full Text] [Related]
4. Systemic rapamycin without loading dose for restenosis prevention after coronary bare metal stent implantation.
Stojkovic S; Ostojic M; Nedeljkovic M; Stankovic G; Beleslin B; Vukcevic V; Orlic D; Arandjelovic A; Kostic J; Dikic M; Tomasevic M
Catheter Cardiovasc Interv; 2010 Feb; 75(3):317-25. PubMed ID: 20049961
[TBL] [Abstract][Full Text] [Related]
5. Firebird and cypher sirolimus-eluting stents and bare metal stents in treatment of very long coronary lesions.
Fan L; Chen LL; Lin CG; Peng YF; Zheng XC; Luo YK; Zhang FL; Chen JH; Yan XP; Huang ZR
Chin Med J (Engl); 2008 Aug; 121(16):1518-23. PubMed ID: 18982862
[TBL] [Abstract][Full Text] [Related]
6. Comparison of effectiveness and safety of sirolimus-eluting stents versus bare-metal stents in patients with diabetes mellitus (from the Italian Multicenter Randomized DESSERT Study).
Maresta A; Varani E; Balducelli M; Varbella F; Lettieri C; Uguccioni L; Sangiorgio P; Zoccai GB;
Am J Cardiol; 2008 Jun; 101(11):1560-6. PubMed ID: 18489933
[TBL] [Abstract][Full Text] [Related]
7. Outcomes of paclitaxel-eluting stent implantation in patients with stenosis of the left anterior descending coronary artery.
Dangas G; Ellis SG; Shlofmitz R; Katz S; Fish D; Martin S; Mehran R; Russell ME; Stone GW;
J Am Coll Cardiol; 2005 Apr; 45(8):1186-92. PubMed ID: 15837247
[TBL] [Abstract][Full Text] [Related]
8. Oral rapamycin to prevent human coronary stent restenosis: a pilot study.
Guarda E; Marchant E; Fajuri A; Martínez A; Morán S; Mendez M; Uriarte P; Valenzuela E; Lazen R
Am Heart J; 2004 Aug; 148(2):e9. PubMed ID: 15309012
[TBL] [Abstract][Full Text] [Related]
9. Role of oral rapamycin to prevent restenosis in patients with de novo lesions undergoing coronary stenting: results of the Argentina single centre study (ORAR trial).
Rodríguez AE; Rodríguez Alemparte M; Vigo CF; Fernández Pereira C; Llauradó C; Vetcher D; Pocovi A; Ambrose J
Heart; 2005 Nov; 91(11):1433-7. PubMed ID: 15774608
[TBL] [Abstract][Full Text] [Related]
10. A comparison of clinical and angiographic outcomes after Excel bioabsorbable polymer versus Firebird durable polymer rapamycin-eluting stent for the treatment of coronary artery disease in a "real world" setting: six-month follow-up results.
Liu HB; Xu B; Qiao SB; Yang YJ; Ma WH; Qin XW; Yao M; Wu YJ; Yuan JQ; Chen J; You SJ; Dai J; Xia R; Li JJ; Chen JL; Gao RL
Chin Med J (Engl); 2007 Apr; 120(7):574-7. PubMed ID: 17442205
[TBL] [Abstract][Full Text] [Related]
11. Long-term clinical outcomes after sirolimus-eluting stent implantation for treatment of restenosis within bare-metal versus drug-eluting stents.
Whan Lee C; Kim SH; Suh J; Park DW; Lee SH; Kim YH; Hong MK; Kim JJ; Park SW; Park SJ
Catheter Cardiovasc Interv; 2008 Apr; 71(5):594-8. PubMed ID: 18311841
[TBL] [Abstract][Full Text] [Related]
12. [Treatment of lesions with a high risk of stenosis. Comparative study in 300 patients of rapamycin- and Paclitaxel-eluting polymer-based stents, and bare metal stents].
de la Torre Hernández JM; Sainz Laso F; Ruisánchez C; Zueco J; Figueroa A; Colman T
Rev Esp Cardiol; 2005 Mar; 58(3):262-9. PubMed ID: 15766448
[TBL] [Abstract][Full Text] [Related]
13. A multicenter, randomized study to test immunosuppressive therapy with oral prednisone for the prevention of restenosis after percutaneous coronary interventions: cortisone plus BMS or DES versus BMS alone to eliminate restenosis (CEREA-DES) - study design and rationale.
Ribichini F; Tomai F; De Luca G; Boccuzzi G; Presbitero P; Pesarini G; Ferrero V; Ghini AS; Pastori F; De Luca L; Zavalloni D; Soregaroli D; Garbo R; Franchi E; Marino P; Minelli M; Vassanelli C
J Cardiovasc Med (Hagerstown); 2009 Feb; 10(2):192-9. PubMed ID: 19377384
[TBL] [Abstract][Full Text] [Related]
14. A polymer-free dual drug-eluting stent in patients with coronary artery disease: a randomized trial vs. polymer-based drug-eluting stents.
Byrne RA; Mehilli J; Iijima R; Schulz S; Pache J; Seyfarth M; Schömig A; Kastrati A
Eur Heart J; 2009 Apr; 30(8):923-31. PubMed ID: 19240066
[TBL] [Abstract][Full Text] [Related]
15. 5-year clinical outcomes after sirolimus-eluting stent implantation insights from a patient-level pooled analysis of 4 randomized trials comparing sirolimus-eluting stents with bare-metal stents.
Caixeta A; Leon MB; Lansky AJ; Nikolsky E; Aoki J; Moses JW; Schofer J; Morice MC; Schampaert E; Kirtane AJ; Popma JJ; Parise H; Fahy M; Mehran R
J Am Coll Cardiol; 2009 Sep; 54(10):894-902. PubMed ID: 19712798
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of the 2.25-mm sirolimus-eluting Bx Velocity stent in the treatment of patients with de novo native coronary artery lesions: the SIRIUS 2.25 trial.
Moses JW; Nikolsky E; Mehran R; Cambier PA; Bachinsky WB; Leya F; Kuntz RE; Popma JJ; Schleckser P; Wang H; Cohen SA; Leon MB;
Am J Cardiol; 2006 Dec; 98(11):1455-60. PubMed ID: 17126649
[TBL] [Abstract][Full Text] [Related]
17. Long-term clinical benefit of sirolimus-eluting stent implantation in diabetic patients with de novo coronary stenoses: long-term results of the DIABETES trial.
Jiménez-Quevedo P; Sabaté M; Angiolillo DJ; Alfonso F; Hernández-Antolín R; SanMartín M; Gómez-Hospital JA; Bañuelos C; Escaned J; Moreno R; Fernández C; Fernández-Avilés F; Macaya C;
Eur Heart J; 2007 Aug; 28(16):1946-52. PubMed ID: 17562666
[TBL] [Abstract][Full Text] [Related]
18. Treatment of diffuse in-stent restenosis with drug-eluting stents vs. intracoronary beta-radiation therapy: INDEED Study.
Park SW; Lee SW; Koo BK; Park DW; Lee SW; Kim YH; Lee CW; Hong MK; Kim JJ; Mori K; Lansky AJ; Mintz GS; Lee MM; Park SJ
Int J Cardiol; 2008 Dec; 131(1):70-7. PubMed ID: 18190986
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of oral sirolimus to inhibit in-stent intimal hyperplasia.
Brito FS; Rosa WC; Arruda JA; Tedesco H; Pestana JO; Lima VC
Catheter Cardiovasc Interv; 2005 Apr; 64(4):413-8. PubMed ID: 15789385
[TBL] [Abstract][Full Text] [Related]
20. Factors predictive of cardiac events and restenosis after sirolimus-eluting stent implantation in small coronary arteries.
Lee CW; Suh J; Lee SW; Park DW; Lee SH; Kim YH; Hong MK; Kim JJ; Park SW; Park SJ
Catheter Cardiovasc Interv; 2007 May; 69(6):821-5. PubMed ID: 17191211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
